• Product name
    Anti-Fibronectin antibody [BC-1]
    See all Fibronectin primary antibodies
  • Description
    Mouse monoclonal [BC-1] to Fibronectin
  • Host species
  • Specificity
    ab154210 recognizes Human EDB+Fibronectin.
  • Tested applications
    Suitable for: IHC-Fr, ELISA, WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Fibronectin purified from WI38VA cultured cell medium

  • Epitope
    Within the Fibronectin type III repeat 7, unmasked by the inclusion of the adjacent extra-domain B, in ED-B+Fibronectin isoform



Our Abpromise guarantee covers the use of ab154210 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use a concentration of 0.1 - 5 µg/ml.
ELISA Use a concentration of 0.1 - 5 µg/ml.
WB Use a concentration of 0.1 - 5 µg/ml.
ICC/IF Use a concentration of 0.1 - 5 µg/ml.


  • Function
    Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts.
    Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.
  • Tissue specificity
    Plasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular FN (dimeric or cross-linked multimeric forms), made by fibroblasts, epithelial and other cell types, is deposited as fibrils in the extracellular matrix. Ugl-Y1, Ugl-Y2 and Ugl-Y3 are found in urine.
  • Involvement in disease
    Glomerulopathy with fibronectin deposits 2
  • Sequence similarities
    Contains 12 fibronectin type-I domains.
    Contains 2 fibronectin type-II domains.
    Contains 16 fibronectin type-III domains.
  • Developmental stage
    Ugl-Y1, Ugl-Y2 and Ugl-Y3 are present in the urine from 0 to 17 years of age.
  • Post-translational
    It is not known whether both or only one of Thr-2064 and Thr-2065 are/is glycosylated.
    Forms covalent cross-links mediated by a transglutaminase, such as F13A or TGM2, between a glutamine and the epsilon-amino group of a lysine residue, forming homopolymers and heteropolymers (e.g. fibrinogen-fibronectin, collagen-fibronectin heteropolymers).
    Phosphorylated by FAM20C in the extracellular medium.
    Proteolytic processing produces the C-terminal NC1 peptide, anastellin.
  • Cellular localization
    Secreted, extracellular space, extracellular matrix.
  • Information by UniProt
  • Database links
  • Alternative names
    • CIG antibody
    • Cold insoluble globulin antibody
    • Cold-insoluble globulin antibody
    • DKFZp686F10164 antibody
    • DKFZp686H0342 antibody
    • DKFZp686I1370 antibody
    • DKFZp686O13149 antibody
    • ED B antibody
    • Fibronectin 1 antibody
    • FINC antibody
    • FINC_HUMAN antibody
    • FN antibody
    • FN1 antibody
    • FNZ antibody
    • GFND antibody
    • GFND2 antibody
    • LETS antibody
    • Migration stimulating factor antibody
    • MSF antibody
    • Ugl-Y3 antibody
    see all


  • Immunohistochemistry (frozen sections) analysis of Human glioblastoma (a and c) and Human normal brain (b) tissues labeling fibronectin with ab154210 antibody at 5 µg/ml.


This product has been referenced in:
  • Gao F  et al. CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing ß-catenin. J Exp Clin Cancer Res 36:70 (2017). Read more (PubMed: 28521777) »
  • Han Z  et al. Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer. Nat Commun 8:692 (2017). Read more (PubMed: 28947734) »

See all 5 Publications for this product

Customer reviews and Q&As

Thank you for contacting us.

I found two antibodies that note ED-B domain in the specificity, ab154210 and ab154211.



Read More

Thank you once again for your enquiries.

I can confirm we are adding two new antibodies to our catalog, for detection of the EDB domain of fibronectin. These should be available in the next week or two. The following links to the online data...

Read More


Sign up